 |
| Glaxo the Ghostwriter? |
The New York Times is running with an incredible story this morning. Once again it features GlaxoSmithKline.
Documents obtained by US attorney's, Baum Hedlund, show how a 269-page book, “Recognition and Treatment of Psychiatric Disorders: A Psychopharmacology Handbook for Primary Care,” was heavily influenced by GSK [then SmithKline Beecham]
The preface of the book acknowledged that an "unrestricted grant' has been provided from a major pharmaceutical company. But Glaxo had much more involvement than the book described.
Duff Wilson of the New York Times writes:
The book’s listed co-authors were Dr. Charles B. Nemeroff, chairman of psychiatry at the University of Miami medical school since 2009 and Emory University before that, and Dr. Alan F. Schatzberg, who was chairman of psychiatry at the Stanford University School of Medicine from 1991 until last year.
The letter documenting the relationship between Dr. Nemeroff, a writing company and SmithKline was dated Feb. 4, 1997. It and a “preliminary draft” of the book, dated Feb. 21, 1997, and adding Dr. Schatzberg’s name were released Monday by the Project on Government Oversight, a Washington advocacy group. They were attached to a letter of complaint to Dr. Francis S. Collins, director of the National Institutes of Health. In the letter, Danielle Brian, executive director of the project, and Paul Thacker, an investigator, formerly with the staff of Senator Charles Grassley of Iowa, also cited other examples of what they termed ghostwriting and asked the N.I.H. for better policing of such practices.
FULL STORY HERE
Fid
PAPERBACK COMING SOON.
PROMOTIONAL VIDEO HERE
No comments: